---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-026043"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2022-07-20T23:59:59+00:00"
generated_at: "2026-06-24T11:08:21.259620+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Assembly Bio halts vebicorvir, cuts workforce 30%, CFO exits, extends cash to H1 2024

## Summary
- Discontinues vebicorvir (VBR) based on interim combo study data showing no benefit in viral parameters.
- Advancing next-gen core inhibitors ABI-H3733 (Phase 1b data H2 2022) and ABI-4334 (Phase 1a starts H2 2022).
- Workforce reduced ~30% (~70 FTEs); CFO Michael Samar departs Aug 12; COO Jason Okazaki becomes President & COO.
- Restructuring costs ~$1.6M; cash runway extended into first half of 2024.
- Prioritizes research: HBV/HDV entry inhibitor, IFNAR agonist, two new viral targets (Q3 2022).

## SEC filing metadata
- accession: 0001564590-22-026043
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2022-07-20T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000156459022026043/0001564590-22-026043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000156459022026043/asmb-8k_20220719.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-026043
- JSON: https://secwatch.observer/filing/0001564590-22-026043.json
- Plain text: https://secwatch.observer/filing/0001564590-22-026043.txt

## Key facts
- Executive change
  Michael P. Samar departed as Chief Financial Officer at ASSEMBLY BIOSCIENCES, INC..
  - Action: departed
  - Role: Chief Financial Officer
  source text: Michael P. Samar will depart his roles as the Company's Chief Financial Officer, principal financial officer and principal accounting officer effective August 12, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1426800/000156459022026043/0001564590-22-026043-index.htm
- Executive change
  Jason A. Okazaki changed role as President and Chief Operating Officer at ASSEMBLY BIOSCIENCES, INC..
  - Action: promoted
  - Role: President and Chief Operating Officer
  source text: on July 19, 2022, the Board promoted Mr. Okazaki to President and Chief Operating Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1426800/000156459022026043/0001564590-22-026043-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.